RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cue Biopharma Stock

Cue Biopharma Stocks 2025

Cue Biopharma Stocks

45.75 M

Ticker

CUE

ISIN

US22978P1066

WKN

A2JAT5

In 2025, Cue Biopharma had 45.75 M outstanding stocks, a 0% change from the 45.75 M stocks in the previous year.

The Cue Biopharma Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e45.75
2029e45.75
2028e45.75
2027e45.75
2026e45.75
2025e45.75
2024e45.75
202345.75
202235.65
202131.29
202028.69
201922.04
201820.13
201716.64
201616.64
201516.64

Cue Biopharma shares outstanding

The number of shares was Cue Biopharma in 2024 — This indicates how many shares 45.755 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cue Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cue Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cue Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cue Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cue Biopharma Aktienanalyse

What does Cue Biopharma do?

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years. Cue Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Cue Biopharma's Shares Outstanding

Cue Biopharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Cue Biopharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Cue Biopharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Cue Biopharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Cue Biopharma stock

How many stocks are there of Cue Biopharma?

The current number of stocks of Cue Biopharma is 45.75 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Cue Biopharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Cue Biopharma evolved in recent years?

The number of shares of Cue Biopharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Cue Biopharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Cue Biopharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Cue Biopharma pay?

Over the past 12 months, Cue Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cue Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Cue Biopharma?

The current dividend yield of Cue Biopharma is .

When does Cue Biopharma pay dividends?

Cue Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cue Biopharma?

Cue Biopharma paid dividends every year for the past 0 years.

What is the dividend of Cue Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cue Biopharma located?

Cue Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cue Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cue Biopharma from 1/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/21/2025.

When did Cue Biopharma pay the last dividend?

The last dividend was paid out on 1/21/2025.

What was the dividend of Cue Biopharma in the year 2024?

In the year 2024, Cue Biopharma distributed 0 USD as dividends.

In which currency does Cue Biopharma pay out the dividend?

The dividends of Cue Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cue Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cue Biopharma

Our stock analysis for Cue Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.